A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
1 . This was a r and omized , double-blind comparison of the efficacy and safety of venlafaxine and fluoxetine in out patients with major depression . 2 . Three hundred fourteen patients were r and omly assigned to either venlafaxine 37.5 mg twice daily or fluoxetine 20 mg once daily for a maximum of 8 weeks . 3 . If the response was inadequate after two weeks of treatment , the dosage of venlafaxine could be increased to 75 mg twice daily . 4 . A clinical response , defined as at least a 50 % decrease from baseline in the total HAM-D score , was attained at week 6 in 72 % of patients on venlafaxine and 60 % of patients on fluoxetine ( p = 0.023 ) . 5 . Among patients who increased their dose at 2 weeks , venlafaxine was significantly ( p < 0.05 ) superior from week 3 onward on the HAM-D. 6 . Venlafaxine 75 mg daily is comparable to fluoxetine , but at 150 mg daily , it may be superior to fluoxetine in out patients with major depression who do not respond early to treatment
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .